drtarsh

Who is a cardio-oncologist? Looking after the hearts of cancer patients before, during and long after cancer treatment.

🚨 St. Francis Heart Center, NY Cardio-Oncology Journal Club #CardioOnc Dr. Marcely Bonatto (Pontifical Catholic University, Brazil 🇧🇷) presents SARAH Trial ✅ In patients with ⬆️ troponin during chemo, ARNI ⬇️ subclinical LV dysfunction (by GLS): opci.live/cardio-oncolog…

Following #InternationalWomenDay, we highlight the intersection of cancer & #CVhealth in👩 This paper from #EHJ shows that #BreastCA may promote #AFib via tumour-secreted factors, suggesting 🫀effects beyond therapy-related cardiotoxicity 🔗:doi.org/10.1093/eurhea… @escardio

📢Current issue of the #EHJ features a Focus on Cardio-Oncology🫀 Discover recently accepted papers and accompanying editorials with new insights into cardiovascular complications of cancer therapies and the care of patients with 🦀 🔗Link in comments @ehj_ed @slumberbell

Calling all #ACC26 and #HOPA26 attendees! Join us on Wed, 3/26 at Arnaud's New Orleans for drinks, delicious hors d'oeuvres, and an opportunity to meet colleagues from the #CardioOncology Community. Register: [link] @ACCinTouch @JHOPjournal #ACC #HOPA #cardioonc #healthcareconference

Read the latest from the great @ymartei! Patients with HIV and breast cancer in Botswana show a high burden of 🫀 risk and early signs of 🫀 dysfunction, underscoring the need for stronger #cardioonc surveillance: tinyurl.com/mrytyfmt @PennCardiology @PennCancer @PennMDForum

NEW CONSENSUS OUT 🫀Atrial Cardiomyopathy is distinct entity marked by structural, functional & electrical abnormalities → AF, HF & adverse CV events. Clinical assessment alone isn’t enough. 🎥 Multimodality imaging is key
✅ Early detection
✅ Risk stratification @escardio

📰 BREAKING NEWS 📰 The European Heart Rhythm Association has released their 2025 survey on how atrial fibrillation (AF) is being treated in cancer patients and survivors. Read the study: academic.oup.com/europace/artic… #cardioonc #cardiooncology #cardiology #atrialfibrillation

@SaadMahmoodMD @NatRevCardiol @Nature @datsunian @StFrancis_LI @CHS_LI @ICOSociety Congratulations!

Excited to share our Review on cardiotoxicities of T cell therapies in @NatRevCardiol @Nature Many thanks to @datsunian for leading this effort #CardioOnc @StFrancis_LI @CHS_LI @ICOSociety

@datsunian @NatRevCardiol @uclaCVfellows @MichaelR21 @A_SteinMerlob @UCLAHealthJCCC @SaadMahmoodMD @md_addison @IntMedAbel @DOM_UCLA @dgsomucla @gcfmd @ICOSociety @SarjuGanatraMD @UCLAHealth Congratulations!

Great @NatRevCardiol review by @uclaCVfellows #bruinhearts chief @MichaelR21, @A_SteinMerlob & @UCLAHealthJCCC #cardioonc colleagues 🔎how cellular therapies impact♥️health. Many avenues to 🔎 as this evolving bioimmunotechnology as cancer indications⬆️ rdcu.be/e5k6t

@NatRevCardiol Congratulations @md_addison

New online! Cardiotoxicity of T cell immunotherapies dlvr.it/TR74rr

📆 COMING UP THIS SPRING: @MSKCancerCenter will be hosting its annual Cardio-Oncology Summit May 21-22 in New York City, featuring a talk by new IC-OS President @Dr_Mike_Fradley. Learn More About the Event: MSK.org/Cardio-Onc #cardioonc #cardiooncology #healthcareconference

Please join us & the @PennCancer community on May 20, 2026 for the Thalheimer Center for Cardio-Oncology Patient Symposium! Open to patients, families, caregivers & advocates. 🫀🎗️ For more information & registration: tinyurl.com/ycxn5un9 @PennMedicine @PennCardiology

🚨🎙️ NEW PODCAST 🚨🫀 On the latest episode of #AllThingsCardioOncology, Dan Lenihan & @abdelcards sit down with @AabuzaidDr to discuss: “Using Imaging in the Early Detection of Amyloidosis” 🔍🧬 🎧 Tune in: tinyurl.com/yb5dd6fd #CardioOnc #CardioTwitter #Amyloidosis

@avirupguha @DocHariKris @TarekNahle @neerajaiims @ICOSociety @OncBrothers @PCF_Science @ZEROCancer @ProstateUK @AHAScience @CDMRP Congratulations

Big day in the poster hall for our group! @DocHariKris and I shared 6 posters today spanning cardio-oncology + multi-omics in prostate cancer: connecting imaging, adiposity, immune remodeling, proteomics, and cardio–kidney–metabolic (CKM) risk. @TarekNahle @neerajaiims @GACancerCenter @anantm Poster lineup: •T1 MRI / radiomics: Skeletal muscle radiomic features on prostate T1-weighted MRI and association with major adverse cardiac events (MACE) @anantm •Obesity-associated epigenetic remodeling under androgen deprivation therapy (ADT) and implications for cardiometabolic risk @ImmunologyAU •CyTOF: CyTOF immune profiling: how obesity shapes biphasic immune remodeling (CD45+ circulating cells) during ADT @ImmunologyAU •Proteomics: Proteomic remodeling after ADT: how age modifies innate immune/complement–ECM pathways @mayo •CardioKidneyMetabolic Syndrome: CKM syndrome stages in prostate cancer and prognostic significance for CV morbidity/mortality •MRI T2 microenvironment: Periprostatic adipose microenvironment remodeling in aggressive prostate cancer (atlas-based geometric analysis) @anantm Really appreciated all the thoughtful questions and conversations: always energizing to share the work and hear new perspectives. If you’re here, come say hi! #ProstateCancer #CardioOncology #Radiomics #Epigenetics #CyTOF #Proteomics #CKM #CancerResearch #TranslationalScience #GU26 @ASCOPost @ASCO @OelsayedMD @EmoryAIHumanity . All abstracts out in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

Elevated Lp(a) increases the risk of abdominal aortic aneurysm (AAA), independent of #ApoB. Using UK Biobank & genetic analyses, Sharma et al. in #JACCBTS provide evidence that supports Lp(a) as a causal risk factor & potential therapeutic target for AAA. jacc.org/doi/10.1016/j.…

@HanZhuMD @JACCJournals Congratulations Han!

Grateful for the ongoing discussion in @JACCJournals - our reply to letters about troponin screening emphasizes pragmatic application of surveillance data in patients receiving immunotherapy Thanks to all for engaging with this important topic🏥jacc.org/doi/abs/10.101…

We are looking to recruit an echo faculty member @PMunkCardiacCtr. We have a busy echo program with >35K echos per year with diverse pathology. Great city! Tremendous research opportunities. Please apply if interested or email me with questions: shorturl.at/U0Uqn

🫀🦀When ACS & cancer coexist, the situation becomes challenging and full of uncertainties🤔 the #ESCCardioOnc and #EAPCI are dedicated to give best advices @escardio @ESC_Lavinia @ESCardioOnco

Excellent #EAPCI & #ESCCardioOnco joint session on #PCI in patients w/ cancer & ACS #EAPCI26 Clinical decisions must balance ischemic risk, bleeding risk & cancer prognosis. Want to learn more? Join #ESCardioOnco26 in Vienna, 19-20 June 26: escardio.org/events/council… @escardio